Ratings by Guggenheim (Charles Zhu)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/2/2024 | MacroGenics | MGNX | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2023 | MacroGenics | MGNX | Upgrade | Buy (Neutral) |
5.44 (15.46) |
184.19% | Details | |
| 7/24/2023 | Nuvalent | NUVL | New Coverage | Buy (N/A) |
44.73 (62.01) |
38.63% | Details | |
| 7/10/2023 | Protera Therapeutics | TARA | New Coverage | Buy (N/A) |
2.32 (2.63) |
13.36% | Details | |
| 3/17/2023 | MacroGenics | MGNX | Downgrade | Neutral (Buy) |
6.99 (15.46) |
121.17% | Details | |
| 1/3/2023 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Neoleukin Therapeutics | NLTX | Downgrade | Neutral (Buy) |
0.51 (3.49) |
584.31% | Details | |
| 12/12/2022 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 11/23/2022 | MacroGenics | MGNX | Upgrade | Buy (Neutral) |
6.37 (15.46) |
142.7% | Details | |
| 11/15/2022 | Neoleukin Therapeutics | NLTX | Downgrade | Neutral (Buy) |
0.54 (3.49) |
546.3% | Details | |
| 10/27/2022 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2022 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/16/2022 | POINT Biopharma Global Inc. | PNT | New Coverage | Buy (N/A) |
8.67 (12.50) |
44.18% | Details | |
| 8/15/2022 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 7/18/2022 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2022 | Cogent | COGT | New Coverage | Buy (N/A) |
8.99 (6.47) |
-28.03% | Details | |
| 6/2/2022 | Repare Therapeutics | RPTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2022 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2022 | Zymeworks | ZYME | Upgrade | Buy (Neutral) |
7.03 (8.76) |
24.61% | Details | |
| 5/4/2022 | MacroGenics | MGNX | Downgrade | Neutral (Buy) |
7.75 (15.46) |
99.48% | Details | |
| 3/28/2022 | Tango Therapeutics Inc. | TNGX | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | Repare Therapeutics | RPTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | Neoleukin Therapeutics | NLTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/7/2021 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2021 | MacroGenics | MGNX | New Coverage | Buy (N/A) |
19.25 (15.46) |
-19.69% | Details | |
| 11/17/2021 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
28.65 (39.50) |
37.87% | Details | |
| 11/17/2021 | Zymeworks | ZYME | New Coverage | Neutral (N/A) |
19.89 (8.76) |
-55.96% | Details | |
| 11/10/2021 | Repare Therapeutics | RPTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2021 | Xencor, Inc. | XNCR | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2021 | Tango Therapeutics Inc. | TNGX | New Coverage | Buy (N/A) |
12.00 (7.09) |
-40.92% | Details | |
| 8/2/2021 | PMV Pharmaceuticals Inc. | PMVP | New Coverage | Buy (N/A) |
34.85 (1.60) |
-95.41% | Details | |
| 6/28/2021 | Repare Therapeutics | RPTX | New Coverage | Buy (N/A) |
33.40 (3.17) |
-90.51% | Details | |
| 4/16/2021 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2021 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
21.73 (36.94) |
70% | Details |
